Prevalence of Anemia among Patients with Solid Cancer at the Time of Diagnosis in Saudi Arabia
Clinical Laboratory · 2026
DOI: 10.7754/clin.lab.2025.250944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Laboratory, 2026. Verfasst von Haytham Dahlawi und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Neoplasms, Anemia.
Abstract (Originalsprache)
BACKGROUND: Cancer represents a significant global health challenge, with elevated incidence and mortality rates, particularly in Saudi Arabia. Anemia frequently manifests as a common complication in patients diagnosed with solid tumors, often remaining undiagnosed. This study aims to evaluate the prevalence of anemia in individuals recently diagnosed with solid tumors, addressing the lack of comprehensive data on this issue. METHODS: A cross-sectional study was conducted using the records of 508 newly diagnosed cancer patients at King Abdulaziz Medical City (2014 - 2024). Eligible patients had confirmed histological diagnoses and no prior cancer treatment. Data included demographics, tumor types, and blood parameters (RBC, hemoglobin, hematocrit, MCV, MCH). Anemia was defined as hemoglobin < 11.5 g/dL in females and < 13.0 g/dL in males. RESULTS: Among the 508 patients analyzed, 47.9% were classified as anemic. Microcytic hypochromic anemia (MCHC) was the most prevalent subtype, observed in 25.2% of patients. Colorectal-related malignancies - including colon, rectal, and sigmoid cancers - showed the highest prevalence of MCHC anemia, suggesting chronic gastrointestinal blood loss and iron deficiency as major contributors. In contrast, breast, endometrial, and skin cancers exhibited predominantly non-anemic profiles. CONCLUSIONS: Anemia was prevalent in 47.9% of newly diagnosed solid tumor patients, most commonly in colorectal cancers (colon 61%, sigmoid 58%, rectal 52%), with microcytic hypochromic anemia (25.2%) as the leading type. Excluding patients with chronic illnesses and prior treatments allowed a clearer estimate of the true burden. Early screening and management are essential to reduce treatment-induced anemia and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Zitieren
APA
Dahlawi, H., Almasoudi, A. S., Joharji, A. S., Alboraie, L., Alamoudi, D., & Borai, A. (2026). Prevalence of Anemia among Patients with Solid Cancer at the Time of Diagnosis in Saudi Arabia. Clinical Laboratory. https://doi.org/10.7754/clin.lab.2025.250944
Vancouver
Dahlawi H, Almasoudi AS, Joharji AS, Alboraie L, Alamoudi D, Borai A. Prevalence of Anemia among Patients with Solid Cancer at the Time of Diagnosis in Saudi Arabia. Clinical Laboratory. 2026. doi:10.7754/clin.lab.2025.250944
BibTeX
@article{Dahlawi2026,
author = {Dahlawi, Haytham and Almasoudi, Atheer S and Joharji, Afaq S and Alboraie, Luluah and Alamoudi, Doaa and Borai, Anwar},
title = {Prevalence of Anemia among Patients with Solid Cancer at the Time of Diagnosis in Saudi Arabia},
journal = {Clinical Laboratory},
year = {2026},
doi = {10.7754/clin.lab.2025.250944}
}
EUVIMED